How the FDA's 'Cosmetic' vs. 'Drug' Classification Dictates Ingredient Claims and Required Testing

The difference between a cosmetic and a drug comes down to a brand's intended use, dictated entirely by the claims printed on the label and marketing materials. If a skincare product claims to alter the skin's structure or treat a disease, it is regulated as a drug and triggers tens of thousands of dollars in federal fees alongside strict testing mandates. Conversely, if it only claims to beautify or alter appearance, it is a cosmetic and bypasses pre-market approval. The U.S. Food and Drug Administration (FDA) does not classify formulas based on what founders hope they are, but rather on the expressed and implied claims made across all consumer-facing touchpoints.[1]

This distinction forms the foundational economic and legal strategy for every beauty and personal care brand entering the market. A single aggressive headline on a moisturizer can recharacterize an entire product line, shifting it from a low-barrier cosmetic into a highly regulated over-the-counter (OTC) drug. Classification questions often surface during retailer onboarding, Amazon category reviews, or influencer campaign planning, well after formulas and packaging are finalized. Early claim audits cost far less than emergency relabeling, reformulation, or pursuing an OTC drug monograph pathway after a product has already launched.[2]

The regulatory boundary was established by the Federal Food, Drug, and Cosmetic (FD&C) Act of 1938. Under the law, cosmetics are defined as articles intended to be rubbed, poured, sprinkled, or sprayed on, introduced into, or otherwise applied to the human body for cleansing, beautifying, promoting attractiveness, or altering the appearance. Drugs, conversely, are defined as articles intended to diagnose, cure, mitigate, treat, or prevent disease, or to affect the structure or any function of the body. The framework relies heavily on the manufacturer's stated intent rather than just the chemical composition of the ingredients.[1]

In practice, the line is drawn by vocabulary. A brand can legally claim that a cosmetic reduces the appearance of fine lines, hydrates and softens skin, or reduces the look of dark spots. However, if the marketing claims the product increases collagen production to reduce wrinkles, regenerates cells, or heals damaged skin, the FDA views it as a drug. The agency reviews words, images, before-and-after photos, and consumer testimonials collectively to determine intended use, meaning a non-compliant influencer post can trigger a regulatory reclassification just as easily as the primary packaging.[2]

Beauty and wellness brands often launch products as cosmetics while marketing them with therapeutic-sounding benefits, notes Natascia Taken, an attorney specializing in advertising law. She warns that one acne treatment headline can recharacterize an entire product line. Claims that a product treats eczema, psoriasis, hair loss, or pigmentation disorders typically indicate drug intended use, moving the product into a vastly different regulatory regime. Brands attempting to blur this line frequently find themselves the target of federal compliance actions based on improper statements.[2]

Opting for—or accidentally triggering—an OTC drug classification introduces severe financial and operational hurdles. Drugs must generally either receive premarket approval through a New Drug Application (NDA) process or conform to an established FDA monograph. These monographs specify the exact conditions whereby active ingredients are generally recognized as safe and effective, dictating everything from permitted concentrations to mandatory warning labels. Deviating from the monograph requires a brand to prove safety and efficacy through expensive clinical trials. This pharmaceutical-grade compliance ensures public safety but drastically increases the time and capital required to bring a product to market.[1]

Beyond the formulation constraints, the federal overhead is substantial. For fiscal year 2025, the FDA's Over-the-Counter Monograph User Fee Act (OMUFA) requires a Monograph Drug Facility (MDF) to pay an annual registration fee of $37,556. Even brands utilizing a Contract Manufacturing Organization (CMO) face a $25,037 annual fee for the facility. These non-refundable fees apply regardless of the company's size or sales volume, creating a massive barrier to entry for independent formulators attempting to launch therapeutic skincare lines.

The cosmetic pathway avoids these prohibitive pre-market approvals and OMUFA fees, making it the default choice for most startups. Historically, the FDA had limited authority over cosmetics, unable to require registration, mandate safety testing, or issue recalls. The industry operated largely on a self-policing model where brands were responsible for ensuring their products were safe under customary conditions of use. However, the regulatory landscape shifted dramatically with the passage of the Modernization of Cosmetics Regulation Act of 2022 (MoCRA).[1]

MoCRA represents the most significant expansion of the FDA's authority over cosmetics since 1938. While it does not require pre-market approval, it mandates that cosmetic manufacturers register their facilities and list all products with the FDA through the Cosmetics Direct portal. It also grants the agency mandatory recall authority and access to safety records, fundamentally changing how beauty brands must document their supply chains and substantiate the safety of their ingredients. The law brings United States cosmetic regulation closer to the stringent oversight seen in the European Union, prioritizing consumer safety without imposing the full burden of drug classification.[1]

MoCRA also requires the FDA to establish Good Manufacturing Practice (GMP) regulations for cosmetic facilities. While GMP compliance was historically voluntary for cosmetics, it is now becoming a mandatory baseline. The FDA is also developing standardized testing methods for detecting asbestos in talc-containing cosmetics and establishing fragrance allergen labeling requirements, further closing the regulatory gap between cosmetics and drugs. Brands must now maintain robust product safety files, batch records, and traceability logs that prove product safety upon request.[1]

Under MoCRA, the compliance burden for cosmetics has increased, though it remains a fraction of the drug pathway. Industry estimates place initial MoCRA compliance costs for small businesses—those with under $1 million in revenue—between $2,000 and $5,000, with annual maintenance costing $500 to $1,000. Medium-sized brands face initial costs up to $15,000, while large enterprises face initial costs upwards of $50,000 depending on portfolio size. This overhead is manageable for most commercial operations, especially when compared to the mandatory $37,556 OMUFA fee required just to register an OTC drug facility.

A critical component of MoCRA is the requirement for adverse event reporting. A responsible person—typically the manufacturer, packer, or distributor named on the label—must report serious adverse events associated with their cosmetic products to the FDA within 15 business days. A serious adverse event includes outcomes like inpatient hospitalization, significant disfigurement, serious rashes, or significant hair loss. Brands are also required to maintain safety and complaint records for six years, ensuring a paper trail exists if the FDA investigates a safety signal.

Even if a brand successfully navigates the FDA's cosmetic classification, it must still satisfy the Federal Trade Commission (FTC), which polices advertising substantiation. The FTC requires competent and reliable scientific evidence for any objective product claim. While the FDA monitors whether a claim crosses into drug territory, the FTC monitors whether the cosmetic claim is actually true. This dual-agency oversight means that a legally compliant cosmetic claim must still be backed by rigorous data. Brands cannot simply invent percentages or efficacy statistics without risking enforcement actions, fines, or mandatory consumer refunds.

If a cosmetic brand makes a quantitative claim—such as stating a serum reduces wrinkle depth by 27 percent—the FTC expects a controlled human study using validated, instrumented endpoints. This typically involves dermatologist grading alongside tools like a 3D imaging system or corneometer, performed on the finished product rather than just individual ingredients. While this testing is expensive, it remains distinct from the FDA's OTC drug requirements, as it proves a cosmetic appearance change rather than a structural or disease-modifying medical outcome.

Complicating matters further are combination products that meet the definitions of both a cosmetic and a drug. An antidandruff shampoo, for example, is a cosmetic because it is intended to cleanse the hair, but it is also a drug because it is intended to treat dandruff. These dual-purpose items represent a massive segment of the personal care market, offering consumers the convenience of a daily beauty routine combined with a therapeutic medical treatment. However, manufacturing them requires navigating two entirely separate sets of federal statutes simultaneously.[1]

Other common combination products include toothpastes with fluoride, deodorants that function as antiperspirants, and moisturizers marketed with sun-protection claims. These products must comply with the requirements for both categories, including OTC drug facility registration, monograph adherence, and combination labeling. The packaging must list the drug components alphabetically as Active Ingredients, followed by the cosmetic components listed in descending order of predominance as Inactive Ingredients. Brands producing these items pay the full OMUFA facility fees while also managing MoCRA's cosmetic adverse event reporting.[1]

The enforcement environment for misclassified products is increasingly aggressive. Skincare and personal care are heavily policed not just by federal agencies, but by retailers, e-commerce platforms, and class-action litigators. Brands that publish a single regulatory overreach can lose a retail listing, face a takedown on Amazon or TikTok Shop, and trigger a class-action lawsuit in the same quarter. Competitors frequently report misclassified products to the FDA, using regulatory compliance as a weapon to clear shelf space. This heightened scrutiny makes early legal review of all marketing copy a mandatory step in product development.

The choice between a cosmetic and a drug classification represents a strategic trade-off between speed-to-market and clinical authority. The cosmetic route offers lower costs and faster launches but restricts marketing to superficial appearance claims. The OTC drug route allows for powerful, disease-treating claims but requires strict formulation adherence, rigorous testing, and tens of thousands of dollars in annual federal fees. Navigating this divide requires brands to align their marketing ambitions with their compliance budgets long before the first batch is manufactured.[3]